The analyst identified that MYRO has built a double bottom pattern, an indicator of a potential reversal of the current downtrend, which marks a new uptrend.The analyst identified that MYRO has built a double bottom pattern, an indicator of a potential reversal of the current downtrend, which marks a new uptrend.

MYRO Tests $0.005087 Support After Double Bottom Forms, Hinting at a Looming Breakout from Downtrend

For feedback or concerns regarding this content, please contact us at [email protected]
trading-chart

Prominent crypto analyst Sangita today identified a looming double bottom pattern in Myro (MYRO), a formation that suggests a substantial price momentum could be coming. The MYRO token, a meme coin based on the Solana blockchain, has been experiencing market difficulties recently. According to metrics from CoinGecko, MYRO price has been down 32.6% and 6,8% over the past week and month, respectively, showing its downside movement. Also, today the virtual asset recorded a 1.6% decline, currently making its price stand at $0.005087.

The Double Bottom Indicator and What It Means

Currently, Myro’s year price is down by 88.2%. As a result, it has significantly underperformed compared to Dogecoin and other major meme coins like Shiba Inu, MemeCore, PEPE, and others this cycle, raising concerns among investors. One of the main catalysts behind this underperformance is the lack of user interest surrounding overall meme coins over the past year, with MYRO one of the casualties that suffered the most.

The meme coin sector saw significant decreases in 2025 as volatility and macroeconomic concerns caused retail investors to shift away from highly speculative assets. Just to show an indicator of this decline, as of December 19, 2025, the overall market cap of meme coins dropped to $35 billion (the lowest point of the year), representing a 65% fall from the year’s high record. This is a sharp difference compared to the trading pattern noticed during the previous year. On Christmas Day 2024, the market cap of meme assets had reached $100 billion.

In a significant development for crypto markets, the MYRO weekly timeframe now displays a strong double bottom pattern, indicating that the asset is primed to experience potential major market rebounds toward higher resistance levels soon.

Crypto market participants typically consider meme assets as a thermometer (an indicator) of retail risk appetite. The substantial decrease in market cap noted in 2025 signified a more cautious environment in the crypto market during that year due to macro-economic uncertainties like trade tariff concerns witnessed in April, June, and October. This uncertainty adversely affected market sentiment last year.

Today, a top market analyst popularly known as Sangita shared his views on MYRO’s next move, suggesting that a rebound could happen if some technical levels hold. The analyst identified that MYRO appears to be creating a double bottom pattern. The double bottom pattern functions as a bullish reversal signal, showing that the ongoing downtrend is coming to an end, paving the way for an upcoming price trajectory.

MYROUSDThe current prince of Myro is $0.005087.

Analysis Of Factors Behind MYRO’s Looming Surge

The formation of the double bottom pattern on the MYRO trading chart signals an approaching bullish trend, driven by growing token accumulation and building positive market sentiment among crypto users. This shows that retail investors are gradually accumulating MYRO while institutional investors are also adding the token to their portfolios.

The rising buying activity (as identified by the analyst) is set to bolster MYRO prices and enable the token to embark on upcoming sustained upsides. One of the drivers behind this momentum is the growing user appetite for meme coins’ trading since the beginning of the new year. 

Market Opportunity
Myro Logo
Myro Price(MYRO)
$0.003258
$0.003258$0.003258
+0.71%
USD
Myro (MYRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09